FOXD2-AS1 inhibits the proliferation and migration in prostate cancer: an in vitro and in vivo study

FOXD2 Adjacent Opposite Strand RNA 1 (FOXD2-AS1), a long noncoding RNA (lncRNA), exhibits specifically elevated in numerous cancerous cells. Numerous studies have shown that FOXD2-AS1 encourages cellular proliferation, migration and invasion. Nevertheless, the exact mechanism through which FOXD2-AS1 contributes to prostate cancer (PCa) remains unclear. Consequently, we aimed to explore the implications of FOXD2-AS1 on the growth of PCa. Initially, an elevation of FOXD2-AS1 observed in PCa cells (PC-3, DU145 and Lncap) than the prostate normal cell line RWPE2. Then, PC-3 cells were tranafected with shFOXD2-AS1, sh-Numerical Control (shNC) or FOXD2-AS1 to assess the implications of FOXD2-AS. Cell growth was measured with cell counting kit-8 (CCK8) and 5-ethynyl-2′-deoxyuridine (EDU) assays, and cell invasion and migration were assessed by Transwell assays, which demonstrated that FOXD2-AS1 silence impeded proliferation, migration and invasion of PC-3 cells. Additionally, we discovered that FOXD2-AS1 bonded with miR-206/programmed cell death protein 10 (PDCD10) trough analyzing the interaction sites of lncRNA, miRNA and protein. Then, these interaction abilities were confirmed by dual-luciferase reporter assays and RT-qPCR, suggesting FOXD2-AS1 could upregulate the amount of PDCD10 through suppressing miR-206. Furthermore, the role of FOXD2-AS1 silencing on PCa carcinogenesis were assessed. In vivo experiment, shFOXD2-AS1 led to a notable reduction in both the size and weight of PCa. These findings indicated that FOXD2-AS1 silencing effectively hindered the progression of prostate cancer. In conclusion, the upregulation of FOXD2-AS1 was observed in PCa, and the knockdown of FOXD2-AS1 could alleviated tumor development by targeting miR-206 to upregulate PDCD10 expression.

FOXD2-AS1; Prostate cancer; miR-206; PDCD10

[1] Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes & Development. 2018; 32: 1105–1140.

[2] Monika Kuzma, Mária Breznická, Ján Kliment. Improving quality of life in metastatic castration-resistant prostate cancer: the role of androgen receptor axis-targeted agents. Journal of Men’s Health. 2023; 19: 1–7.

[3] Murillo-Garzón V, Kypta R. WNT signalling in prostate cancer. Nature Reviews Urology. 2017; 14: 683–696.

[4] Li W, Xu W, Sun K, Wang F, Wong TW, Kong A. Identification of novel biomarkers in prostate cancer diagnosis and prognosis. Journal of Biochemical and Molecular Toxicology. 2022; 36: e23137.

[5] Herman AB, Tsitsipatis D, Gorospe M. Integrated lncRNA function upon genomic and epigenomic regulation. Molecular Cell. 2022; 82: 2252–2266.

[6] Li R, Wang X, Zhu C, Wang K. LncRNA PVT1: a novel oncogene in multiple cancers. Cellular & Molecular Biology Letters. 2022; 27: 84.

[7] Zhao W, Zhu X, Jin Q, Lin B, Ji R. The lncRNA NEAT1/miRNA-766-5p/E2F3 regulatory axis promotes prostate cancer progression. Journal of Oncology. 2022; 2022: 1866972.

[8] Ferri C, Di Biase A, Bocchetti M, Zappavigna S, Wagner S, Le Vu P, et al. MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer. Journal of Experimental & Clinical Cancer Research. 2022; 41: 20.

[9] Zhang Y, Guo S, Wang S, Li X, Hou D, Li H, et al. LncRNA OIP5-AS1 inhibits ferroptosis in prostate cancer with long-term cadmium exposure through miR-128-3p/SLC7a11 signaling. Ecotoxicology and Environmental Safety. 2021; 220: 112376.

[10] Guo F, Guo R, Zhang L. Downregulation of lncRNA FOXD2-AS1 confers radiosensitivity to gastric cancer cells via miR-1913/SETD1A axis. Cytogenetic and Genome Research. 2022; 162: 10–27.

[11] Liang Y, Wang H, Song R, Yin X. LncRNA FOXD2-AS1 promotes the retinoblastoma cell viability and migration by sponging miR-31. BioMed Research International. 2022; 2022: 7723425.

[12] Zhang Y, Hu J, Zhou W, Gao H. LncRNA FOXD2-AS1 accelerates the papillary thyroid cancer progression through regulating the miR-485-5p/KLK7 axis. Journal of Cellular Biochemistry. 2019; 120: 7952–7961.

[13] Hu W, Feng H, Xu X, Huang X, Huang X, Chen W, et al. Long noncoding RNA FOXD2-AS1 aggravates hepatocellular carcinoma tumorigenesis by regulating the miR-206/MAP3K1 axis. Cancer Medicine. 2020; 9: 5620–5631.

[14] Dong C, Fan B, Ren Z, Liu B, Wang Y. CircSMARCA5 facilitates the progression of prostate cancer through miR-432/PDCD10 axis. Cancer Biotherapy and Radiopharmaceuticals. 2021; 36: 70–83.

[15] Fu X, Zhang W, Su Y, Lu L, Wang D, Wang H. MicroRNA-103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer. The Prostate. 2016; 76: 543–551.

[16] Xu K, Fei W, Huo Z, Wang S, Li Y, Yang G, et al. PDCD10 promotes proliferation, migration, and invasion of osteosarcoma by inhibiting apoptosis and activating EMT pathway. Cancer Medicine. 2023; 12: 1673–1684.